Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study
for the PHranceSCa study group
Research output: Contribution to journal › Article › peer-review
29Scopus
citations
Fingerprint
Dive into the research topics of 'Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study'. Together they form a unique fingerprint.